Hunan Warrant Pharmaceutical Co. Ltd. A (SHG:688799) — Market Cap & Net Worth
Market Cap & Net Worth: Hunan Warrant Pharmaceutical Co. Ltd. A (688799)
Hunan Warrant Pharmaceutical Co. Ltd. A (SHG:688799) has a market capitalization of $1.08 Billion (CN¥7.37 Billion) as of September 21, 2026. Listed on the SHG stock exchange, this China-based company holds position #8614 globally and #2058 in its home market, demonstrating a 19.51% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Hunan Warrant Pharmaceutical Co. Ltd. A's stock price CN¥56.10 by its total outstanding shares 131320000 (131.32 Million). Also see Hunan Warrant Pharmaceutical Co. Ltd. A balance sheet assets for a full breakdown of the balance sheet.
Hunan Warrant Pharmaceutical Co. Ltd. A Market Cap History: 2021 to 2026
Hunan Warrant Pharmaceutical Co. Ltd. A's market capitalization history from 2021 to 2026. Data shows growth from $740.52 Million to $1.08 Billion (2.03% CAGR). Also see cash efficiency ratio of Hunan Warrant Pharmaceutical Co. Ltd. A for how efficiently the company converts equity into cash flow.
Hunan Warrant Pharmaceutical Co. Ltd. A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Hunan Warrant Pharmaceutical Co. Ltd. A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check 688799 stock price and chart for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.57x
Hunan Warrant Pharmaceutical Co. Ltd. A's market cap is 0.57 times its annual revenue
Latest Price to Earnings (P/E) Ratio
4.90x
Hunan Warrant Pharmaceutical Co. Ltd. A's market cap is 4.90 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $740.52 Million | $1.15 Billion | $160.76 Million | 0.65x | 4.61x |
| 2022 | $585.43 Million | $1.29 Billion | $182.80 Million | 0.45x | 3.20x |
| 2023 | $920.90 Million | $1.43 Billion | $211.32 Million | 0.64x | 4.36x |
| 2024 | $804.78 Million | $1.41 Billion | $164.32 Million | 0.57x | 4.90x |
Competitor Companies of 688799 by Market Capitalization
Companies near Hunan Warrant Pharmaceutical Co. Ltd. A in the global market cap rankings as of September 21, 2026. Review tangible equity quality of Hunan Warrant Pharmaceutical Co. Ltd. A to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Hunan Warrant Pharmaceutical Co. Ltd. A by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #612 globally with a market cap of $44.88 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #635 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #670 globally with a market cap of $40.99 Billion USD ( CN¥280.10 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #612 | GALDERMA GROUP AG | NYSE:GALDY | $44.88 Billion | $38.49 |
| #635 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.90 |
| #670 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $40.99 Billion | CN¥43.91 |
Hunan Warrant Pharmaceutical Co. Ltd. A Historical Marketcap From 2021 to 2026
Between 2021 and today, Hunan Warrant Pharmaceutical Co. Ltd. A's market cap moved from $740.52 Million to $ 1.08 Billion, with a yearly change of 2.03%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.08 Billion | +17.61% |
| 2025 | CN¥916.61 Million | +13.90% |
| 2024 | CN¥804.78 Million | -12.61% |
| 2023 | CN¥920.90 Million | +57.30% |
| 2022 | CN¥585.43 Million | -20.94% |
| 2021 | CN¥740.52 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 21st, 2026 the market cap of Hunan Warrant Pharmaceutical Co. Ltd. A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.08 Billion USD |
| MoneyControl | $1.08 Billion USD |
| MarketWatch | $1.08 Billion USD |
| marketcap.company | $1.08 Billion USD |
| Reuters | $1.08 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Hunan Warrant Pharmaceutical Co. Ltd. A
Hunan Warrant Pharmaceutical Co.,Ltd manufactures and sells pharmaceutical products. It offers medicines in the areas of digestive, berating, anti-infection, gynecology, cardiovascular, cerebrovascular, immunology and nephrology, and other fields. Hunan Warrant Pharmaceutical Co.,Ltd was founded in 2001 and is based in Changsha, China.